Pq Bypass

PQ Bypass Unveils New Data From DETOUR I at VIVA 17

Seroba’s investee company, PQ Bypass, today announced data from a subset analysis of the DETOUR I clinical trial during a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), which is taking place September 11-14 in Las Vegas.

The study evaluated the safety and effectiveness of the DETOUR System for treating long-segment (>25cm) blockages in the femoropopliteal artery via a novel, fully percutaneous bypass approach, known as the DETOUR procedure.
The presentation by Sean Lyden, M.D., chairman of the vascular surgery department at Cleveland Clinic, was entitled: Safety and Efficacy of a Novel Percutaneous Bypass Procedure for Long-Segment Femoropopliteal Disease: A Sub-Analysis (>25cm) from the DETOUR I Trial.

Percutaneous femoropopliteal bypass (the DETOUR procedure) is a newly developed procedure that utilizes the proprietary DETOUR System – TORUS Stent Graft, DETOUR Crossing Device and DETOUR Snare – to enable a fully percutaneous bypass of long-segment blockages in the femoropopliteal artery.

The DETOUR procedure creates a pathway around a lesion by placing stent grafts that cross from the femoral artery into the femoral vein and back into the artery.  The new path re-directs oxygen-rich blood around the blockage and restores blood flow to the lower leg and foot of the patient. The restoration of blood flow helps to reduce pain and improve patient mobility, all while limiting the progression of PAD.

About PQ Bypass

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally invasive endovascular solutions.

PQ Bypass is operated by recognized leaders in the medical device industry including veterans from Medtronic, Abbott, Johnson & Johnson, and Stryker. The underlying technology and technique used in the percutaneous DETOUR procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in peripheral artery disease.

Note: The DETOUR System is not available for sale in the U.S.

For more information, please visit www.pqbypass.com or contact Vicky La Touche-Price at Seroba Life Sciences on +353 (0)1 6334028.

Recent Articles

Fusion Pharmaceuticals Appoints New Chief Medical Officer

23 March 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision […]

Read More
Endotronix 025 Lo (002)

Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial

LISLE, IL – February 18, 2020 – Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to […]

Read More
Cancer Killers

Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors

Boston, MA & Hamilton, February 6, 2020.   Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted […]

Read More
The Big Taboo

Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO®

GALWAY, Ireland.  6 February 2020.  Seroba’s portfolio  company, Atlantic Therapeutics, a global medical device manufacturer, today announced that the U.S. […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top